Prescription Drugs: Market & Industry - Kaiser Family Foundation

Sort Documents by:

Document Type:

Date Range:

Prescription Drugs: Market & Industry

Prescription Drug Trends
Trend data for prescription drug coverage, expenditures, and the key factors that contribute to rising prescription spending.

Impact of Direct-to-Consumer Advertising on Prescription Drug Spending
The effects of direct-to-consumer (DTC) advertising on spending for prescription drugs.

Recent Documents: (31 results)

Pages 1 | 2

Public Views on Direct-to-Consumer Prescription Drug Advertising -- May 2008
Mollyann Brodie, Kaiser vice president and director of Public Opinion and Media Research, testified before the House Energy and Commerce Subcommittee on Oversight and Investigations about the public's views of prescription drugs, the pharmaceutical industry, and direct-to-consumer drug advertising.

Public and Physician Views of Direct-to-Consumer Prescription Drug Advertising -- May 2008
This spotlight examines the public's familiarity with prescription drug advertising, their general opinions of these ads, and their experiences talking to doctors about drugs they saw advertised. It also explores these topics from the doctors’ point of view. The spotlight compiles and analyzes public opinion data from Kaiser surveys and other sources.

Views On Prescription Drugs & The Pharmaceutical Industry -- May 2008
Kaiser Public Opinion Spotlight: Views On Prescription Drugs And The Pharmaceutical Industry

Prescription Drug Trends Fact Sheet: May 2007 Update -- May 2007
This updated fact sheet provides trend information about prescription drug expenditures and coverage, key factors that contribute to rising prescription spending, and efforts to contain rising drug costs.

Follow The Pill: Understanding the U.S. Commercial Pharmaceutical Supply Chain -- March 2005
This report describes the U.S. pharmaceutical supply chain, following prescription drugs as they move from manufacturers, to wholesale distributors, to pharmacies, and ultimately to patients.

Cost Containment Strategies For Prescription Drugs: Assessing The Evidence In The Literature -- March 2005
This report describes and reviews various options to address prescription drug spending growth, including a description of each cost-containment strategy, its use by private or public payers, and a discussion of known evidence about its effectiveness or cost-saving potential.

Views On Prescription Drugs And The Pharmaceutical Industry -- February 2005
This Kaiser Health Poll Report uses current and historical public opinion data from the Kaiser Family Foundation and other polling organizations to examine the public’s attitudes towards prescription drugs and pharmaceutical companies.

Americans Value the Health Benefits of Prescription Drugs, But Say Drug makers Put Profits First, New Survey Shows - Toplines -- February 2005
The most recent Kaiser Health Poll Report found that Americans believe prescription drugs are improving their lives, but most also say that the drug industry cares more about profits than people. The current report analyzes the new data as well as related polling information from earlier surveys by the Kaiser Family Foundation and other organizations.

Impact of Pharmaceutical Promotion on the Use of Antidepressant Medication -- December 2004
Two articles evaluate the impact of direct-to-consumer advertising on the use of antidepressants.

Estimates of Medicare Beneficiaries' Out-of-Pocket Drug Spending in 2006 -- November 2004
This report projects the impact of the new Medicare drug benefit on out-of-pocket spending for people who enroll in 2006.

Mollyann Brodie, Kaiser vice president and director of Public Opinion and Media Research, testified before the House Energy and Commerce Subcommittee on Oversight and Investigations about the public's views of prescription drugs, the pharmaceutical industry, and direct-to-consumer drug advertising.

This spotlight examines the public's familiarity with prescription drug advertising, their general opinions of these ads, and their experiences talking to doctors about drugs they saw advertised. It also explores these topics from the doctors’ point of view. The spotlight compiles and analyzes public opinion data from Kaiser surveys and other sources.

Kaiser Public Opinion Spotlight: Views On Prescription Drugs And The Pharmaceutical Industry

This updated fact sheet provides trend information about prescription drug expenditures and coverage, key factors that contribute to rising prescription spending, and efforts to contain rising drug costs.

This report describes the U.S. pharmaceutical supply chain, following prescription drugs as they move from manufacturers, to wholesale distributors, to pharmacies, and ultimately to patients.

This report describes and reviews various options to address prescription drug spending growth, including a description of each cost-containment strategy, its use by private or public payers, and a discussion of known evidence about its effectiveness or cost-saving potential.

This Kaiser Health Poll Report uses current and historical public opinion data from the Kaiser Family Foundation and other polling organizations to examine the public’s attitudes towards prescription drugs and pharmaceutical companies.

The most recent Kaiser Health Poll Report found that Americans believe prescription drugs are improving their lives, but most also say that the drug industry cares more about profits than people. The current report analyzes the new data as well as related polling information from earlier surveys by the Kaiser Family Foundation and other organizations.

Two articles evaluate the impact of direct-to-consumer advertising on the use of antidepressants.

This report projects the impact of the new Medicare drug benefit on out-of-pocket spending for people who enroll in 2006.

View all items >

Pages 1 | 2

Prescription Drugs: Market & Industry

Prescription drugs have been the fastest-growing component of health care spending, a trend that is attributable primarily to increases in the number of prescriptions dispensed and the shift to newer, high-cost drugs. This increased spending is projected to continue in the future.